1 active not recruiting, 1 recruiting. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Ublituximab on Motor Functions in Multiple Sclerosis Ublituximab - Multiple Sclerosis (MS) - Relapsing-remitting | Early Phase 1 | Recruiting | Georgia State University | 25 | 2025-11-13 | 2026-02-09 |
| Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Pembrolizumab - Solid Tumors, Identified by NGS, PCR or IHC | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-20 | 2026-03-05 |
Multiple Sclerosis, Relapsing-Remitting (1) · Pathologic Complete Response (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Multiple Sclerosis (1) · Nervous System Diseases (1)
pembrolizumab (1) · ublituximab (1)
Georgia State University (1) · Memorial Sloan Kettering Cancer Center (1)
United States (2)